Investors
Bonus Biogroup (TASE:BONS) is a clinical-stage biotechnology company developing 'next-generation’, innovative, cost-effective cell therapy solutions for various indications in regenerative medicine with prevalent and unmet clinical needs. Leveraging our proprietary technology platform, we are advancing two lead product candidates - BonoFill and MesenCure - which are currently being evaluated in clinical trials for their potential applications in tissue engineering and cell therapy.
BonoFill
- Currently under clinical evaluation for maxillofacial, dental, and orthopedic applications.
- A Phase II trial for maxillofacial bone defects has been completed, showing a 90% success rate, with a Phase III study planned, pending FDA clearance.
- An additional Phase II trial for orthopedic indications is ongoing. Enrollment completion is expected in 2025, with interim results expected in 2026.
MesenCure
- Evaluated in a completed Phase II clinical trial for its ability to modulate inflammation and support lung recovery in severely ill patients with pneumonia and respiratory distress due to COVID-19.
- In 2025, the FDA cleared an Investigational New Drug (IND) application for a Phase III trial targeting COVID-19-related pneumonia.
- The Company is working on amending the clinical protocol to broaden the scope of the Phase III trial to include patients with respiratory distress from all causes, including ARDS, pending FDA clearance.
Our clinical research is focused on bone regeneration and inflammatory conditions, with ongoing initiatives to expand into additional therapeutic areas. Bonus Biogroup continues to advance a robust clinical pipeline, broaden its research programs, and explore strategic regulatory pathways to bring its investigational therapies to market.
FOR MORE INVESTOR RELATION INFORMATION
Press Release, Announcements publication and more
